Curis, Inc. (CRIS)
-NasdaqGM 3.43 
0.01(0.29%) 4:00PM EDT
| Prev Close: | 3.44 |
|---|
| Open: | 3.42 |
|---|
| Bid: | 2.81 x 3000 |
|---|
| Ask: | 3.51 x 400 |
|---|
| 1y Target Est: | 6.58 |
|---|
| Beta: | 2.29 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 3.36 - 3.50 |
|---|
| 52wk Range: | 2.66 - 5.51 |
|---|
| Volume: | 206,141 |
|---|
| Avg Vol (3m): | 545,758 |
|---|
| Market Cap: | 276.25M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.30 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Competing In The Sport Of Biotechs, Curis Takes Aimat Seeking Alpha(Sun, Jun 16)
- Curis to Present at the 2013 Wells Fargo Securities Healthcare ConferenceGlobeNewswire(Tue, Jun 11)
- Valuing The Potential Of Cancer Drugs: The Case Of Curisat Seeking Alpha(Mon, Jun 3)
- Apple’s Next Court Appointment, Curis Slides on ASCO Presentation, and 3 More Hot Stocksat Wall St. Cheat Sheet(Mon, Jun 3)
- CURIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of SecurityEDGAR Online(Mon, Jun 3)
- Curis Announces CUDC-427 (GDC-0917) Phase I Clinical Data Presented at ASCO 2013 Annual MeetingGlobeNewswire(Mon, Jun 3)
- Curis Announces Appointment of Mani Mohindru, Ph.D., as Vice President of Corporate Strategy and Investor RelationsGlobeNewswire(Fri, May 31)
- Curis to Present at the Jefferies 2013 Global Healthcare ConferenceGlobeNewswire(Thu, May 30)
- Curis, Inc. Presents at 38th Annual Deutsche Bank Health Care Conference, May-29-2013 08:40 AMat Seeking Alpha(Wed, May 29)
- Curis to Present at the Deutsche Bank 38th Annual dbAccess Health Care ConferenceGlobeNewswire(Wed, May 22)
- American Society Of Clinical Oncology Abstracts Point To Potential Profitsat Seeking Alpha(Tue, May 21)
- CURIS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual MeetingGlobeNewswire(Thu, May 16)
- 10 ASCO '13 Abstracts You Can Read Right Nowat TheStreet(Wed, May 15)
- Three of WellPoint's directors resign for personal reasonsat Reuters(Mon, May 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 37.00 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.03 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that ha...
View More